Menu

Image of the Day: Medicinal Millipedes

Certain lemurs in the forests of Madagascar eat millipedes to protect themselves from parasitic infections of the gut.

Jul 31, 2018
Sukanya Charuchandra
A red-fronted lemur (Eulemur rufifrons) chews on millipedes in the Kirindy Forest of Madagascar. 
LOUISE PECKRE

Madagascar’s red-fronted lemurs (Eulemur rufifrons) eat millipedes to both prevent and cure infections caused by some parasites, according to a study published in Primates yesterday (July 30). 

“Eating millipede secretions may be a way of self-medication,” Louise Peckre, a doctoral student at the Leibniz Institute for Primate Research in Germany, says in a statement.  

Besides eating the creatures, the primates also applied munched-up millipedes to the areas surrounding their genitalia and anuses and to their tails. Peckre and colleagues  believe the millipedes produce a compound called benzoquinone, known to repel mosquitoes, which may help the lemurs keep parasites out of their gut and away from their anuses.

L.R. Peckre et al., “Potential self-medication using millipede secretions in red-fronted lemurs: combining anointment and ingestion for a joint action against gastrointestinal parasites?,” Primates, doi:10.1007/s10329-018-0674-7, 2018.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!